nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

18.04.2023 | themenschwerpunkt

Magenkarzinom

verfasst von: Dr. Krisztina Racz, OA Andras Legner, Dr. Felix Böhme, Prof. Dr. Christian Sebesta

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Magenkarzinome sind relativ häufige Krebserkrankungen. In den letzten Jahren haben sich die Therapieoptionen geändert (sowohl chirurgische, als auch onkologische), deswegen ist es spannend, die Ätiologie, Diagnostik und Therapieoptionen durchzuschauen.

Vorheriger Artikel Neuroendokrine Neoplasien des Gastrointestinaltrakts

Nächster Artikel Die Klimakrise als ethische Herausforderung

Statistik-Austria. https://www.statistik.at/gesundheit/krebserkankungen. Sept. 2021.

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0031-1285293. Sept. 2021.

Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14:1149–55.CrossRefPubMedPubMedCentral

Joshi SS, Badgwell BD. Current treatment und recent progress in gastric cancer. Cancer J Clin. 2021;71(3):264–79.CrossRef

Ikoma N, Lee JH, Bhutani MS, et al. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol. 2017;8:1009–17.CrossRefPubMedPubMedCentral

Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:4332–7.CrossRefPubMed

National Comprehensive Cancer Network (NCCN). NCCN guidelines, version 4.202. Gastric cancer. 2021.

Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project. Gastric Cancer. 2017;20(2):217–25.CrossRefPubMed

Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed

10.

Brierley JD, Gospodarowicz MK, Wittekind C, Hrsg. TNM classification of malignant tumors. 8. Aufl. Hoboken: Wiley-Blackwell; 2016.

11.

Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476–84.CrossRefPubMed

12.

Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–400.CrossRefPubMed

13.

Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMed

14.

Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10(1):1–11.CrossRefPubMed

15.

Kawata N, Kakushima N, Takizawa K, et al. Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Surg Endosc. 2017;31:1607–16.CrossRefPubMed

16.

Al-Batran SE, Homann N, Schmalemberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(suppl):4004.CrossRef

17.

Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, Noh SH, Fong Y, Hyung WJ. Lymphadenectomy with optimum of 29 lymph nodes retrieved associated with improved survival in advanced gastric cancer: a 25,000-patient international database study. J Am Coll Surg. 2017;224(4):546.CrossRefPubMed

18.

Hofheinz RD, Haag GM, Ettrich TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol. 2020;38(15):4502.CrossRef

19.

Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379:315–21.CrossRefPubMed

20.

Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24(9):2679.CrossRefPubMed

21.

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMed

22.

Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.CrossRefPubMed

23.

Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110:275–84.CrossRefPubMedPubMedCentral

24.

Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.CrossRefPubMedPubMedCentral

25.

Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19:1882–7.CrossRefPubMed

26.

. https://www.onkopedia.com/de/onkopedia/guidelines/magenkarzinom/@@guideline/html/index.html#litID0ED5BG. Sept. 2021.

27.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed

28.

Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRefPubMed

29.

Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437–48.CrossRefPubMed

30.

Moehler M, Shitara K, Garrido M, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31(suppl 4):S1191.CrossRef

Titel: Magenkarzinom
verfasst von: Dr. Krisztina Racz
OA Andras Legner
Dr. Felix Böhme
Prof. Dr. Christian Sebesta
Publikationsdatum: 18.04.2023
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 9-10/2023
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-023-01011-x

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9-10/2023

Gastrointestinale Stromatumoren (GIST)

Neuroendokrine Neoplasien des Gastrointestinaltrakts

Editorial WMW 2021

Das Ösophaguskarzinom

Modelle der Integration eines palliativmedizinischen Konzeptes in die onkologische Behandlung

Kolorektales Karzinom